GlobalData on MSN6d
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...
4ABBV : AbbVie's Elahere Cuts Death Risk By 32%...
AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...
PMLive4d
AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial
AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...
pharmaphorum2d
AbbVie builds the case for ovarian cancer drug Elahere
AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...
The American Journal of Managed Care3d
Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer
Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor ...
Medical News Today5d
Elahere interactions: Alcohol, medications, and other factors
Elahere is prescribed for certain types of cancer in adults. These include: fallopian tube cancer ovarian cancer peritoneal cancer An interaction occurs when one substance causes another substance ...
Targeted Oncology5d
Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...